Growth Hormone Secretagogues Explained: The Researcher's Guide to GHRH and GHRP Peptides

The Problem With Just Measuring Growth Hormone

Growth hormone declines with age. That's not controversial — it's one of the most consistent findings in endocrinology. GH secretion rates drop exponentially after puberty, declining from roughly 150 micrograms per kilogram per day during the teenage years to about 25 by age 55. IGF-1 follows along. Body composition shifts — muscle mass decreases, fat (particularly visceral fat) increases. Recovery slows. Sleep quality drops.

The obvious solution, to some minds, is to just replace the GH. Exogenous growth hormone does exactly that. But administering GH directly bypasses the body's own regulatory architecture — and that architecture exists for good reasons. It creates feedback loops, limits excess, and modulates release in a pulsatile, rhythmic pattern that pure exogenous administration doesn't replicate. Secretagogues take a different approach entirely. Rather than providing GH from outside, they stimulate the body to produce and release more of its own.

This distinction matters a lot for how researchers think about these compounds.

The Hypothalamic-Pituitary Axis: A Quick Map

Understanding secretagogues requires a quick map of the relevant biology. Growth hormone secretion is governed by a two-signal system originating in the hypothalamus.

Signal one: GHRH (growth hormone-releasing hormone). This peptide travels from the hypothalamus to the anterior pituitary, where it binds to specific receptors and stimulates GH synthesis and secretion. This is the "go" signal.

Signal two: Somatostatin. This counterbalances GHRH — it's the "stop" signal that prevents continuous GH release and enforces pulsatility. GH is released in pulses, not as a steady trickle, and somatostatin is largely responsible for shaping those pulses.

There's also a third player that was identified more recently: ghrelin. Produced primarily in the stomach, ghrelin binds to a receptor in the pituitary (the GHS receptor, or GHS-R1a) and powerfully stimulates GH release — through a pathway distinct from GHRH. It also suppresses somatostatin activity, which amplifies GH output through a second route.

GH secretagogues divide into two broad classes based on which of these pathways they engage: GHRH analogs (which mimic the first signal) and GHRP/ghrelin mimetics (which engage the ghrelin receptor). Combining them creates synergistic GH release.

GHRH Analogs: CJC-1295 and Sermorelin

Sermorelin

Sermorelin is GHRH(1-29), the biologically active truncated form of native GHRH. It was one of the first synthetic GHRH analogs studied clinically. It works exactly as native GHRH does — binds to pituitary GHRH receptors, stimulates GH production and release. Its half-life is short (minutes), which means it produces a pulsatile GH release pattern that closely mimics natural physiology.

That short half-life is both an asset and a constraint. Physiologically faithful: yes. Practical for sustained GH elevation: not particularly. This drove the development of longer-acting GHRH analogs.

Researchers can explore 22EXO's Sermorelin (5mg) for GHRH pathway investigations.

CJC-1295 (with DAC)

Here's where it gets genuinely interesting from a pharmacology standpoint. CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analog that permanently and covalently binds to serum albumin after administration. Albumin has a long half-life — and when CJC-1295 hitches to it, the peptide's effective half-life extends to approximately 6–8 days.

Teichman et al. published the landmark clinical pharmacology data on this in the Journal of Clinical Endocrinology and Metabolism in 2006. In that randomized, placebo-controlled study of healthy adults, a single injection of CJC-1295 produced 2- to 10-fold increases in mean plasma GH for 6 or more days, and IGF-1 elevations lasting 9–11 days. Multiple doses showed evidence of cumulative effect — IGF-1 stayed elevated above baseline for up to 28 days. No serious adverse reactions were reported.

A separate study examined whether CJC-1295 preserved natural GH pulsatility despite prolonged stimulation — a reasonable concern, given that continuous GHRH stimulation could theoretically blunt pulsatile release. The finding was reassuring: GH pulse frequency and magnitude were unaltered. What changed was basal (trough) GH levels — up 7.5-fold — contributing to an overall 46% increase in mean GH secretion. IGF-1 rose 45%.

This preservation of pulsatility is one of the central arguments for secretagogues over exogenous GH. Pulsatile release has different downstream effects than steady-state elevation, and maintaining it may matter for the receptor sensitivity and signaling dynamics that give GH its biological effects.

CJC-1295 with DAC (5mg) is available from 22EXO for research use.

CJC-1295 Without DAC (Mod-GRF 1-29)

Remove the DAC modification and you get a peptide with a much shorter half-life — roughly 30 minutes rather than 6–8 days. CJC-1295 without DAC (also called Modified GRF 1-29 or Mod-GRF) still offers improved stability over native GHRH(1-29), but its GH release pattern is more acute and pulsatile. Researchers often use it in combination with GHRPs to produce a timed, synergistic GH pulse.

The tradeoffs between the DAC and no-DAC versions — prolonged steady elevation versus acute pulsatile release — represent genuinely different research questions. Neither is simply "better." They produce different GH secretion profiles, and which matters depends on what you're investigating. CJC-1295 without DAC (5mg) is available for research.

GHRP Peptides: Ghrelin Mimetics

The second class of GH secretagogues operates entirely differently — through the ghrelin receptor (GHS-R1a) rather than the GHRH receptor. These compounds were originally developed before ghrelin itself was discovered; ghrelin was actually identified in 1999 partly because researchers were working backward from the existence of these synthetic GHS-R1a agonists to find their natural ligand.

Ipamorelin

Ipamorelin is a pentapeptide — just five amino acids. Raun et al. published the foundational characterization of ipamorelin's pharmacology in the European Journal of Endocrinology in 1998. What made ipamorelin notable was selectivity. Prior GHRPs like GHRP-6 also stimulated GH release, but they simultaneously elevated ACTH and cortisol — stress hormones. Ipamorelin, remarkably, produced GH release comparable to GHRP-6 in both rats and swine without significant effects on ACTH or cortisol levels even at doses more than 200-fold above the ED50 for GH release.

Raun's group described it as "the first GHRP-receptor agonist with a selectivity for GH release similar to that displayed by GHRH." That selectivity profile — strong GH, minimal cortisol — is why ipamorelin became arguably the most studied GHRP for research purposes.

Ipamorelin (5mg) is available from 22EXO.

GHRP-6

GHRP-6 is an older compound — studied since the 1980s — that also binds the ghrelin receptor and releases GH with substantial potency. Its main difference from ipamorelin is that it does stimulate appetite (via ghrelin receptor signaling in the hypothalamus) and can elevate cortisol and prolactin. For some research questions this is irrelevant. For others it's a significant confounder.

GHRP-6 remains relevant in research precisely because it's older and more extensively characterized in the literature. Some findings on it extrapolate reasonably to ipamorelin; others don't. GHRP-6 (5mg) is available from 22EXO for comparison research.

The Synergy Between GHRH Analogs and GHRPs

When you combine a GHRH analog with a GHRP, something interesting happens: GH release is dramatically larger than either compound produces alone. This isn't additive — it's synergistic. The two pathways interact at multiple levels. GHRH stimulates GH synthesis and release directly. GHRPs engage the GHS-R1a receptor and simultaneously suppress somatostatin activity, removing the "brake" on GH secretion. Together, they produce a GH pulse that can exceed what either achieves alone by several-fold.

Walker et al. reviewed GH secretagogue research in aging in Clinical Interventions in Aging in 2006, noting that GHRH analogs and GHRPs each demonstrated ability to increase GH and IGF-1 levels in aging adults, with preliminary evidence for effects on body composition and physical function. The field was young then; the mechanistic rationale for combination approaches was established, but long-term human clinical trial data was sparse.

That gap hasn't fully closed. Mechanistic studies are solid. Long-term controlled human outcome data — the kind that would let researchers say definitively what happens to muscle mass, fat distribution, sleep quality, or cognition with sustained secretagogue use — remains thin.

For researchers investigating combination protocols, 22EXO's CJC-1295 No-DAC / Ipamorelin Blend (5mg) provides both compounds in a single preparation.

Why Secretagogues Rather Than Exogenous GH?

This is worth addressing directly because it comes up constantly in research contexts. Exogenous recombinant growth hormone works — it raises GH and IGF-1 levels, improves body composition. So why bother with secretagogues?

Several reasons, and they're not trivial. First, secretagogues only work if the pituitary is functional — they depend on intact GH secretory capacity. This is actually a feature, not a limitation: they can't produce supraphysiologic GH levels because they're working through native regulation. Natural feedback loops remain operative. Second, secretagogues preserve pulsatility. The biological effects of pulsatile GH differ from sustained GH elevation, and those differences matter for receptor sensitivity and downstream signaling. Third, exogenous GH suppresses the body's own GH axis — chronic exogenous GH administration leads to pituitary downregulation. Secretagogues avoid this by stimulating rather than replacing endogenous production.

None of this means secretagogues are appropriate for all research questions, or that exogenous GH has no place. They're different tools addressing different aspects of GH biology.

Purity, Sourcing, and Research Integrity

A brief but important note. The GH secretagogue space has a significant supply quality problem. Many products sold online bear little resemblance to their labels in terms of actual peptide content, purity, or sequence fidelity. For research purposes, this is not a minor concern — inconsistent raw material produces inconsistent results, and unreproducible findings contaminate the literature.

HPLC verification and third-party testing are the baseline for research-grade material. All 22EXO peptides undergo third-party purity testing. See our related articles on CJC-1295 DAC vs no-DAC pharmacokinetics, CJC-1295/Ipamorelin stack research, and research peptide dosing protocols for additional context.